Ascentage Pharma Group International
HKEX:6855.HK
44.2 (HKD) • At close November 12, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Ascentage Pharma Group International |
Symbool | 6855.HK |
Munteenheid | HKD |
Prijs | 44.2 |
Beurswaarde | 13,855,570,911 |
Dividendpercentage | 0% |
52-weken bereik | 15.42 - 48.85 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Dajun Yang M.D., Ph.D. |
Website | https://www.ascentagepharma.com |
An error occurred while fetching data.
Over Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)